LBA42 Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma
S. Kim(Moffitt Cancer Center), Andrew S. Brohl(Moffitt Cancer Center), Kenneth Y. Tsai(Moffitt Cancer Center), Evan Wuthrick(Moffitt Cancer Center), Joseph Markowitz(University of South Florida), Matthew N. Mills(Moffitt Cancer Center), Nikhil I. Khushalani(Roswell Park Comprehensive Cancer Center), Vernon K. Sondak(Advanced Dermatology), Rupak Thapa(Moffitt Cancer Center), Khaled Dibs(The Ohio State University), Dukagjin Blakaj(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), D-T. Chen(Moffitt Cancer Center), Trevor Rose(Moffitt Cancer Center), J.J. Caudell(Moffitt Cancer Center), Claire F. Verschraegen(The Ohio State University), Casey Liveringhouse(Moffitt Cancer Center), J. Russell(University of Utah Hospital), Ahmad A. Tarhini(UPMC Hillman Cancer Center), J. Messina(Moffitt Cancer Center), Zeynep Eroglu(Moffitt Cancer Center)
Cited by 0
Related Papers
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
|Annals of Oncology|2016|822
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
|JAMA Oncology|2015|656
Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies
|Cancer|2016|375
Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas
|Cell Reports|2018|366